NEWS & UPDATES

Recruitment: We are 62% of the way to achieving our target (5000 patients)!

​

​

​

​

​

Check out Mount Sinai's article on the ICARUS-IBD study: 

https://reports.mountsinai.org/article/gi2021-02-icarus

​

Our Publications:

​

McGregor CG, Adams A, Sadler R, et al.

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

Gut Published Online First: 12 February 2021. doi: 10.1136/gutjnl-2021-324116.

​

Wellens J., Colombel J-F., Satsangi JJ., Wong S-Y.

SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges.

J Crohn’s Colitis 2021:1–36. Doi: 10.1093/ecco-jcc/jjab046.

​

Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.

Gastroenterology. 2021 Apr 20: S0016-5085(21)00648-X. doi: 10.1053/j.gastro.2021.04.025.

​

Anna L McNaughton, Robert S Paton, Matthew Edmans, Jonathan Youngs, Judith Wellens, Craig P Thompson

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.medRxiv 2021.05.04.21256571; doi: https://doi.org/10.1101/2021.05.04.21256571

​

​